Acoustic Monitor Detects Cardiac Decompensation Risk
By HospiMedica International staff writers Posted on 10 Mar 2021 |
Image: The AUDICOR acoustic cardiography device (Photo courtesy of Inovise Medical)
A new heart failure management system detects cardiac decompensation remotely in patients who have been previously hospitalized.
The Inovise Medical (Portland, OR, USA) AUDICOR is an acoustic cardiography device designed to non-invasively assess electro-mechanical activation time (EMAT). The acoustic signals are acquired via a hand-held device that connects to a smart phone and uploaded for remote analysis in the cloud. The result is a series of proprietary cardiac acoustic biomarkers that provide actionable data that physicians can use in order to modify patient therapies (such as changing drug dosages) before a significant deterioration that requires further hospitalization can occur.
The device works by simultaneously recording and algorithmically interpreting digital electrocardiogram (ECG) and acoustic data acquired by a multi-axial sound sensor. By measuring systolic time intervals and diastolic sounds, the AUDICOR can provide a reliable assessment of cardiac hemodynamics. Parameters produced include those needed to assess EMAT and systolic function, including Q wave onset to the S1 interval, the presence of a third heart sound (S3), and systolic dysfunction index (SDI), a combination of EMAT, S3, QRS duration, and QR interval.
“The most significant advantages of this new technology are enhanced ease of use, eliminated risks of surgical complications, and significantly reduced costs compared to permanently implanted physiologic sensors currently on the market,” said Peter Bauer, PhD, CEO of Inovise Medical.
“This technology promises to enhance the management of heart failure patients and keep them out of the hospital,” said Professor Michael Mirro, MD, of Indiana University (Bloomington, IN, USA). “Early detection of potential problems outside of the hospital can allow clinicians to modify the patients' therapeutic regimens and maintain their stable condition.”
The third heart sound (S3), also known as ventricular gallop, occurs after the mitral valve opens to allow passive filling of the left ventricle (LV); if the LV is not overly compliant (as is in most adults), the S3 will not be loud enough to be heard. Thus, S3 heart sound is often a sign of systolic heart failure, as it usually indicates the myocardium is overly compliant, resulting in a dilated LV. According to the company, the technology can be extended for use in other diseases, including LV hypertrophy, constrictive pericarditis, sleep apnea, and ventricular fibrillation.
Related Links:
Inovise Medical
The Inovise Medical (Portland, OR, USA) AUDICOR is an acoustic cardiography device designed to non-invasively assess electro-mechanical activation time (EMAT). The acoustic signals are acquired via a hand-held device that connects to a smart phone and uploaded for remote analysis in the cloud. The result is a series of proprietary cardiac acoustic biomarkers that provide actionable data that physicians can use in order to modify patient therapies (such as changing drug dosages) before a significant deterioration that requires further hospitalization can occur.
The device works by simultaneously recording and algorithmically interpreting digital electrocardiogram (ECG) and acoustic data acquired by a multi-axial sound sensor. By measuring systolic time intervals and diastolic sounds, the AUDICOR can provide a reliable assessment of cardiac hemodynamics. Parameters produced include those needed to assess EMAT and systolic function, including Q wave onset to the S1 interval, the presence of a third heart sound (S3), and systolic dysfunction index (SDI), a combination of EMAT, S3, QRS duration, and QR interval.
“The most significant advantages of this new technology are enhanced ease of use, eliminated risks of surgical complications, and significantly reduced costs compared to permanently implanted physiologic sensors currently on the market,” said Peter Bauer, PhD, CEO of Inovise Medical.
“This technology promises to enhance the management of heart failure patients and keep them out of the hospital,” said Professor Michael Mirro, MD, of Indiana University (Bloomington, IN, USA). “Early detection of potential problems outside of the hospital can allow clinicians to modify the patients' therapeutic regimens and maintain their stable condition.”
The third heart sound (S3), also known as ventricular gallop, occurs after the mitral valve opens to allow passive filling of the left ventricle (LV); if the LV is not overly compliant (as is in most adults), the S3 will not be loud enough to be heard. Thus, S3 heart sound is often a sign of systolic heart failure, as it usually indicates the myocardium is overly compliant, resulting in a dilated LV. According to the company, the technology can be extended for use in other diseases, including LV hypertrophy, constrictive pericarditis, sleep apnea, and ventricular fibrillation.
Related Links:
Inovise Medical
Latest Critical Care News
- AI Doubles Medical Professionals’ Accuracy in Reading EEG Charts of ICU Patients
- Flexible Device Enables Sweat Gland Stimulation and Simultaneous Biosensing
- WHO Publishes First Global Guidelines to Reduce Bloodstream Infections from Catheter Use
- Innovative Material Paves Way for Next-Generation Wearable Devices
- Wireless Electronic Suture Enables Postoperative Long-Term Monitoring Of Soft Tissue
- Transcatheter Valve Replacement Outcomes Similar To Surgery, Finds Study
- Revascularization Improves Life Quality in Chronic Limb-Threatening Ischemia, Finds Study
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD